Literature DB >> 26773112

Physical and Mental Functioning in Patients with Established Rheumatoid Arthritis over an 11-year Followup Period: The Role of Specific Comorbidities.

Joëlle van den Hoek1, Leo D Roorda2, Hendriek C Boshuizen2, Gerard J Tijhuis2, Geertrudis A van den Bos2, Joost Dekker2.   

Abstract

OBJECTIVE: To investigate the longterm association of a wide range of comorbidities with physical and mental functioning in patients with rheumatoid arthritis (RA).
METHODS: Longitudinal data over a period of 11 years were collected from 882 patients with RA. Somatic comorbidity and comorbid depression were measured at baseline, with a questionnaire including 20 chronic diseases and with the Center for Epidemiologic Depression Scale, respectively. Physical functioning was measured at 5 timepoints with a disease-specific measure [Health Assessment Questionnaire (HAQ)] and a generic measure [physical scales of the Medical Outcomes Study Short Form-36 (SF-36)]. Mental functioning was measured with the mental scales of the SF-36. To determine the association of baseline-specific comorbidities with functioning over time, we performed longitudinal analyses.
RESULTS: At baseline, 72% percent of the patients were women, mean age ± SD was 59.3 ± 14.8 years, median RA disease duration was 5.0 years, and 68% had ≥ 1 comorbid condition. The effect of comorbid conditions was more apparent when physical functioning was measured with SF-36, a disease-generic measure, compared with the HAQ, a disease-specific measure. Circulatory conditions and depression were associated (p < 0.05) with worse physical functioning according to the HAQ. Respiratory conditions, musculoskeletal conditions, cancer, and depression were associated (p < 0.05) with worse physical functioning according to the SF-36. Respiratory conditions and depression were associated with worse mental functioning.
CONCLUSION: Patients with specific comorbid conditions have an increased risk of low functioning in the long term. Targeted attention for these specific comorbid conditions by clinicians is recommended.

Entities:  

Keywords:  COMORBIDITY; DEPRESSION; LONGITUDINAL; MENTAL FUNCTIONING; PHYSICAL FUNCTIONING; RHEUMATOID ARTHRITIS

Mesh:

Year:  2016        PMID: 26773112     DOI: 10.3899/jrheum.150536

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

Review 1.  cDNA phage display for the discovery of theranostic autoantibodies in rheumatoid arthritis.

Authors:  Patrick Vandormael; Patrick Verschueren; Liesbeth De Winter; Veerle Somers
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

2.  Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study.

Authors:  J van den Hoek; H C Boshuizen; L D Roorda; G J Tijhuis; M T Nurmohamed; G A M van den Bos; J Dekker
Journal:  Rheumatol Int       Date:  2016-12-28       Impact factor: 2.631

3.  The Patient-Reported Outcomes Thermometer-5-Item Scale (5T-PROs): Validation of a New Tool for the Quick Assessment of Overall Health Status in Painful Rheumatic Diseases.

Authors:  Fausto Salaffi; Marco Di Carlo; Marina Carotti; Sonia Farah
Journal:  Pain Res Manag       Date:  2018-10-23       Impact factor: 3.037

4.  The impact of different rheumatic diseases on health-related quality of life: a comparison with a selected sample of healthy individuals using SF-36 questionnaire, EQ-5D and SF-6D utility values.

Authors:  Fausto Salaffi; Marco Di Carlo; Marina Carotti; Sonia Farah; Alessandro Ciapetti; Marwin Gutierrez
Journal:  Acta Biomed       Date:  2019-01-15

5.  Synovial Fluid-Derived Extracellular Vesicles of Patients with Arthritides Contribute to Hippocampal Synaptic Dysfunctions and Increase with Mood Disorders Severity in Humans.

Authors:  Clara Cambria; Francesca Ingegnoli; Eleonora Borzi; Laura Cantone; Lavinia Agra Coletto; Alessandra Stefania Rizzuto; Orazio De Lucia; Sabrina Briguglio; Massimiliano Ruscica; Roberto Caporali; Valentina Bollati; Massimiliano Buoli; Flavia Antonucci
Journal:  Cells       Date:  2022-07-23       Impact factor: 7.666

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.